1|INTRODUCTION Cancer has emerged as a significant threat to human life,and its incidence and mortality are increasing rapidly.As clinicians increasingly seek to noninvasively investigate tumor phenotypes and evaluate...1|INTRODUCTION Cancer has emerged as a significant threat to human life,and its incidence and mortality are increasing rapidly.As clinicians increasingly seek to noninvasively investigate tumor phenotypes and evaluate functional and molecular responses to therapy,the combination of diagnostic im-aging with targeted therapy is becoming more widely implemented[1].Targeted radionuclide therapy involves the use of small molecules,peptides,and/or antibodies as carriers for therapeutic radionuclides,with these being referred to as radiopharmaceuticals.Radiopharmaceuti-cals,also known as molecular probes in nuclear medicine,play a vital role in clinical diagnosis and therapy.Currently,there are numerous radiopharmaceuticals approved or under research worldwide for a wide range of indications.At the end of March 2022,there were 60 radiopharmaceuticals approved for marketing by the Food and Drug Administration(FDA)[2](Supplemental Table)[2].As of October 2023,42 radiopharmaceuticals have been approved for marketing by the National Medical Products Administration(NMPA)[3].However,there remains an urgent need to identify new targets and new drug molecules to advance the process of radiopharma-ceutical research and development.展开更多
基金Capital's Funds for Health Improvement and Research,Grant/Award Numbers:2022‐2Z‐2154,2022‐2Z‐2155Youth talent support program,Grant/Award Number:A002863。
文摘1|INTRODUCTION Cancer has emerged as a significant threat to human life,and its incidence and mortality are increasing rapidly.As clinicians increasingly seek to noninvasively investigate tumor phenotypes and evaluate functional and molecular responses to therapy,the combination of diagnostic im-aging with targeted therapy is becoming more widely implemented[1].Targeted radionuclide therapy involves the use of small molecules,peptides,and/or antibodies as carriers for therapeutic radionuclides,with these being referred to as radiopharmaceuticals.Radiopharmaceuti-cals,also known as molecular probes in nuclear medicine,play a vital role in clinical diagnosis and therapy.Currently,there are numerous radiopharmaceuticals approved or under research worldwide for a wide range of indications.At the end of March 2022,there were 60 radiopharmaceuticals approved for marketing by the Food and Drug Administration(FDA)[2](Supplemental Table)[2].As of October 2023,42 radiopharmaceuticals have been approved for marketing by the National Medical Products Administration(NMPA)[3].However,there remains an urgent need to identify new targets and new drug molecules to advance the process of radiopharma-ceutical research and development.
